Supporting Emerging Biopharma (EBP)
Much of today’s investigational cancer therapeutics originates in small biotechnology companies, most of which are innovative and agile by nature, but also lack the financial horsepower, resources, and infrastructure of multinational pharmaceutical entities.
Multiple Myeloma External Comparator Cohort
Real-world data (RWD) in Oncology proves to be a vital source for clinical decisions and program decisions. COTA partnered with a Top 5 Pharma company to curate a custom multiple myeloma real-world cohort for use as a synthetic control arm regulatory filing.
Underutilization of Genomic Sequencing
Despite advances in liquid biopsies, standard-of-care remains tissue-based genotyping, an approach that is relatively invasive, inconvenient, slow, and expensive
